Nature Medicine
1, 205 - 206 (1995)
doi:10.1038/nm0395-205
A peppy response to PEPI resultsLoretta P. Finnegan1, Jacques Rossouw1
& William R. Harlan1
1Woman's Health Initiative, Office of Research on Women's Health Office ofDisease Prevention National Insitutes of Health Bethesda, Maryland 20892-9110, USA Recent publication of the results of the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial has led to the Woman's Health Initiative(WHI) to rethink the protocols for its own large trial.
REFERENCES
- Writing group for PEPI tria. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J.A.M.A. 273, 199−208 (1995). | ISI |
- Grady, D. et al Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. intern. Med., 117, 1016−1037 (1992). | PubMed | ISI | ChemPort |
- Wentz, W.B. Progestin therapy in endometrial hyperplasia. Gynecol. Oncol. 2, 362−367 (1974). | Article | PubMed | ChemPort |
- Smith, D.C., Prentice, R., Donovan, J.T. & Herrman, W.L. Association of exogenous estrogen and endometrial carcinoma. New Engl. J. Med. 293, 1164−1167 (1975). | PubMed | ISI | ChemPort |
- Ziel, H.K. & Finkle, W.D. Increased risk of endometrial carcinoma among users of conjugated estrogens. New Engl. J. Med. 293, 1167−1170 (1975). | PubMed | ISI | ChemPort |
- ACOG Technical Bulletin 166 (American College of Obstetricians and Gynecologists, Washington, DC, 1992).
- American College of Physicians. Ann. intern. Med. 117, 1038−1041 (1992). | ISI |
- Woodruff, J.D. & Pickar, J.H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am. J. Obstet. Gynecol. 170, 1213−1223 (1994). | PubMed | ISI | ChemPort |
- Simon, J.A. et al. The absorption of micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Obstet. Gynecol. 60, 26−33 (1993). | ChemPort |
|
